Mr. Li is the General Manager of Zennova Pharmaceuticals (Chengdu) Co Ltd. He brings 28 years of senior executive leadership in Chinese pharmaceutical industry, with successful track record in sales & marketing and company management experience.

In his career, he had built and managed over 1000 sales & marketing team crossing all provinces of China market. As the sales & marketing leader, he helped Beijing Garlin Pharmaceutical Co., Ltd to achieve over 5 billion annual sales for its cholesterol drug, which is the very first drug to achieve the 5 billion mark in China pharm history. Mr. Li also served as senior management role in companies like Sichuan Taiji Pharmaceutical Co., Ltd. of Taiji Group, Sichuan O.S.I. Pharmaceutical Co., Ltd. of Haixing Group Being the seasoned marketing and management expert in the Chinese pharmaceutical industry, Mr. Li is recognized and invited to be the industry expert in multiple top consulting companies such as CAPVISION and FIRSTKNOW. Focusing on the combination of theory and practice, he has published professional training and teaching books such as "The Training Book of Five Dimensional Management Skills for decisive middle managers ", "The Practical Skills to Improve Medical Sales Representatives" and "The practical Skills for Regional Managers to improve Sales in Target Hospitals" etc. He has a profound experience in the transformation and development of China's pharmaceutical industry in last 30 years.

Mr. Li graduated from West China Medical University with BS degree in Medicine Sciences, focusing in Preventive Healthcare.

Dr. Adam Feng is the co-founder & Chief Scientific Officer at Zennova Pharma Group. Dr. Feng is recognized as one of the most experienced experts in pharmaceutical research & development, especially the advance technology of drug formulation & complex generic drug development. He has served as the Head of R&D in several global pharmaceutical companies.

Dr. Feng has extensive experience in pharmaceutical product development, new technology innovation, people management and project management. Since the early 1990s, he has worked in many world-renowned pharmaceutical companies including Merck, TEVA, and Takeda in the United States where he was the Director of R&D. When Dr. Feng worked as the Sr. VP and Head of Global R&D in PuraCap Pharmaceuticals, he directly managed the company's four research and development centers in US & China. Under his leadership, there were over 60 preion drugs developed in various dosage forms, including tablets, granules, soft capsules etc. It is the largest portfolio of FDA drug pipeline among all Chinese Pharmaceutical companies.

Dr. Feng has obtained more than 20 patents from US, China and globally in broad fields of drug formulation, drug analysis, process development, etc. He has a diverse and successful experience in innovative new drug (NDA) and generic drug (ANDA) development and product life cycle management expertise.

Through 26-year industry experience including senior management role, Dr. Feng has an in-depth understanding of FDA regulations, cGMP compliance and DEA (United States Drug Control Agency) compliance. Dr. Feng has led numerous new drug development projects in his previous careers. He achieved over 50 drug approval from US FDA. This accomplishment ranks him as one of the top scientist in Chinese pharmaceutical industry. Especially, two innovative new drugs NDAs (Colcrys for the treatment of gout and Fibricor for the reduction of triglycerides) were quickly reach over US$500 million in sales after they were approved and launched in US market. Dr. Feng also pioneers in complex nano-particle formulation products and multiparticulate controlled-release products.

Dr. Feng received his PhD degree in pharmaceutics from Long Island University, and his BS degree in Chemistry from Beijing Normal University. He was honored with the “3551 Leading Excellent Talent Award" in China.

Graduated from the Department of Chemistry/Natural Sciences at Akron University in the United States, with two MBA degrees from Philly Dickens University; Having 36 years of rich experience in the pharmaceutical industry and senior commercial development experience, including in the fields of raw materials, small and large molecule formulations, and generic drugs; Completed 9 company mergers and acquisitions; And has rich experience in various pharmaceutical products and ANDA cooperation and mergers and acquisitions; Participated in multiple matchmaking negotiations for startups and CDMO; Manage multiple business departments and lead multiple strategic planning processes; We have deep network relationships with pharmaceutical companies in the global market, including Europe, the United States, India, Israel, and China.

Over 30 years of work experience in the pharmaceutical industry. Since the 1980s, he has served as the factory director, director, general manager, and other positions in multiple foreign-funded pharmaceutical enterprises, with extremely rich practical management experience and outstanding achievements in pharmaceutical production and pharmaceutical factory operation management. He has particularly rich experience in managing large pharmaceutical production enterprises, familiar with domestic and foreign regulations on pharmaceutical production management and product transfer registration, and has practical experience in registration transfer, equipment selection, factory construction, pilot scale up, and large-scale production of various high-end complex formulations, sterile lyophilized and water injection formulations, pre filled injection formulations, sterile raw materials, and other varieties. He has led the management of four pharmaceutical factories in accordance with FDA standards for construction, GMP certification, and production operation management.

He has a doctor's degree from University of Science and Technology of China and 7 years of core pharmaceutical experience, as well as more than 10 years of rich general R&D experience and R&D specific project management experience. Dr. Ye Xiang is a senior professional in regulation and R&D management, with a doctor's degree from the University of Science and Technology of China and 7 years of core pharmaceutical experience, as well as more than 10 years of rich general R&D experience and R&D specific project management experience. At the same time, he has business acumen and rich experience in team building, scheduling, data analysis, Change control, regulatory review, project selection and project control. As a strong leader, he is also adept at motivating the team to provide effective solutions and the highest level of performance, and can demonstrate the motivation and commitment required to achieve goals and meet urgent deadlines.